There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arcus Biosciences (RCUS – Research Report), Spectrum Pharmaceuticals (SPPI – Research Report) and Eli Lilly & Co (LLY – Research Report) with bullish sentiments.
Arcus Biosciences (RCUS)
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Arcus Biosciences today and set a price target of $51.00. The company’s shares closed last Monday at $28.92.
According to TipRanks.com, Goldstein is a 2-star analyst with an average return of
Arcus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $43.57, a 48.7% upside from current levels. In a report issued on November 23, Citigroup also maintained a Buy rating on the stock with a $37.00 price target.
See the top stocks recommended by analysts >>
Spectrum Pharmaceuticals (SPPI)
JMP Securities analyst Reni Benjamin reiterated a Buy rating on Spectrum Pharmaceuticals today and set a price target of $4.00. The company’s shares closed last Monday at $0.48, close to its 52-week low of $0.36.
According to TipRanks.com, Benjamin has 0 stars on 0-5 stars ranking scale with an average return of
Spectrum Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $3.00, implying a 575.8% upside from current levels. In a report issued on November 25, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.
Eli Lilly & Co (LLY)
BMO Capital analyst Evan Seigerman maintained a Buy rating on Eli Lilly & Co today and set a price target of $396.00. The company’s shares closed last Monday at $367.64, close to its 52-week high of $369.80.
According to TipRanks.com, Seigerman is a 4-star analyst with an average return of
Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $383.69, representing a 5.6% upside. In a report issued on November 17, Credit Suisse also initiated coverage with a Buy rating on the stock with a $395.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RCUS:
